Diaphyseal femoral fatigue fracture associated with bisphosphonate therapy-3 more cases

Acta Orthopaedica

Volumn 82, Issue 1, 2011, Pages 112-113

  Osugi, Kaiya ^a   Miwa, Shigeki ^b   Marukawa, Shinobu ^c   Marukawa, Kouhei ^c   Kawaguchi, Yoshiharu ^d   Nakato, Shinichi ^a  

^a ASAHI GENERAL HOSPITAL   (Japan)

^b Miwa Orthopedic Clinic   (Japan)

^c Marukawa Hospital   (Japan)

^d UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; RALOXIFENE; RISEDRONIC ACID;

AGED; ARTICLE; BONE RADIOGRAPHY; CASE REPORT; DIAPHYSIS; FEMALE; FEMUR FRACTURE; HUMAN; INTRAMEDULLARY NAILING; POSTMENOPAUSE OSTEOPOROSIS; STRESS FRACTURE;

AGED; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; ETIDRONIC ACID; FEMALE; FEMORAL FRACTURES; FRACTURES, STRESS; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 79751506038     PISSN: 17453674     EISSN: 17453682     Source Type: Journal    
DOI: 10.3109/17453674.2010.539500     Document Type: Article

References (10)

1. Aspenberg P. Bisphosphonates and fatigue fractures. IBMS BoneKEy 2009; 6: 465-9.
2. Black D M, Schwartz A V, Ensrud K E, Cauley J A, Levis S, Quandt S A, Sat-terfeld S, Wallace R B, Bauer D C, Palermo L, Wehren L E, Lombardi A, Santora A C, Cummings S R, FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Interven-tion Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006; 296: 2927-38. (Pubitemid 46021497)
3. Black D M, Kelly M P, Genant H K, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010; 362: 1761-71.
4. Ciarella T E, Fyhrie D P, Parftt A M. Effects of vertebral bone fragility and bone formation rate on the mineralization levels of cancellous bone from white females. Bone 2003; 32: 311-5. (Pubitemid 36349535)
5. Ensrud K E, Barrett-Connor E L, Schwartz A, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 2004; 8: 1259-69. (Pubitemid 41094366)
6. Goh S K, Yang K Y, Koh J S, et al. Subtrochanteric insuffciency fractures in patients on alendronate therapy. J Bone Joint Surg (Br) 2007; 89: 349-53. (Pubitemid 46563912)
7. Kwek E B K, Goh S K, Koh J S B, et al. An emerging pattern of subtrochan-teric stress fractures: A long-term complication of alendronate therapy. Injury 2008; 39: 224-31.
8. Mashiba T, Hirano T, Turner C H, et al. Suppressed bone turnover by bisphos-phonates increases microdamage accumulation and reduces biomechanical properties in dog rib. J Bone Miner Res 2000; 15: 613-20. (Pubitemid 30174014)
9. Odvina C V, Levy S, Rao S, Zerwekh J E, Sudhaker Rao D. Unusual mid-shaft fractures during long term bisphosphonate therapy. Clin Endocrinol 2010; 72:161-8.
10. Schilcher J, Aspenberg P. Incidence of steress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop 2009; 80 (4): 413-5.